Relating to assay reagents

ABSTRACT

We have discovered that the stability of a dilute peroxidase-containing solution is greatly enhanced by the addition of a specific substrate for the peroxidase, in the absence of peroxide. We provide a peroxidase-containing reagent consisting of a buffered aqueous solution comprising a peroxidase or a peroxidase conjugate and a specific substrate for the peroxidase, in the absence of peroxide. The peroxidase may be a free peroxidase but for assay purposes is preferably a peroxidase bound to a specific binding component of an assay, to form a peroxidase conjugate. The peroxidase conjugate is preferably a conjugate between a peroxidase and an antigen or an antibody, most preferably an antibody. The peroxidase is preferably horseradish peroxidase.

This is a continiuation of application Ser. No. 08/261,007, filed Jun.4, 1994, now U.S. Pat. No. 5,736,333 which is a continuation ofapplication Ser. No. 08/115,666, filed Sep. 2, 1993, which is acontinuation of application Ser. No. 07/928,638, filed Aug. 14, 1992,which is a continuation of application Ser. No. 07/724,518, filed Jun.28, 1991, which is a continuation of application Ser. No. 07/494,960,filed Mar. 15, 1990, which is a continuation of application Ser. No.07/334,799, filed Apr. 3, 1989, which is a continuation of applicationSer. No. 07/156,580, filed Feb. 17, 1988, which is a Rule 60continuation of 06/937,061, filed Nov. 6, 1986, all now abandoned.

This invention relates to improved assay reagents and in particular toan improved peroxidase-containing reagent, an improvedperoxidase-substrate reagent and to an assay reagent kit containing oneor both such reagents.

The peroxidases are a group of enzymes which catalyse the oxidation ofspecific substrates by peroxide. Certain substrates, when oxidised inthis way, become strong-chromophors, generating intense colour. Theperoxidases have been widely used as labels in assay application;usually is conjugates with specific binding assay components. Thepresence of such a labelled component can be readily-detected by addinga substrate solution comprising the specific substrate and a peroxide.An example of an assay employing such a conjugate is the enzyme labelledimmunosorbent assay (ELISA), versions of which employ a peroxidase boundto an antibody.

A significant problem in the preparation of assay kits includingperoxidase reagents is the long term stability of the peroxidases,particularly in the dilute solutions commonly used for assay. Stabilitymay be enhanced by the inclusion of serum proteins but it has becomecommon to provide peroxidase-containing reagents either in a lyophilisedform or as a concentrated solution. The provision of the reagent in thisform adds a further manipulation step to the protocol for performing agiven assay. It is also known to stabilise peroxidase-containingreagents using serum protein and either 4-aminoantipyrine (see UnitedStates patent specification 4448882) or 8-anilino-1-naphthalenesulphonic acid (see British patent specification 2066823).

One of the more widely used peroxidases is horse-radish peroxidase(hereinafter referred to as HRP), for which a specific substrate istetramethylbenzidine (hereinafter referred to as TMB). TMB is anon-hazardous colourless substrate which forms an intensely colouredoxidation product in the presence of a peroxide and HRP. It is howeveronly sparingly soluble in aqueous solution, and at room temperaturetends to crystallize from solution at concentrations suitable for assay.This reduces the availability of TMB for reaction with peroxide andhence reduces the sensitivity of the assay. The known assay kits, whichemploy TMB as a substrate for HRP, provide a multi-componentsubstrate-reagent pack which must be mixed shortly before use. Anyexcess reagent cannot be stored for subsequent use.

The catalytic action of peroxidase, as mentioned above, requires thepresence of both a specific substrate and a peroxide. We have discoveredthat the stability of a dilute peroxidase-containing solution is greatlyenhanced by the addition of a specific substrate for the peroxidase, inthe absence of peroxide.

According to a first aspect of the invention we provide aperoxidase-containing reagent consisting of a buffered aqueous solutioncomprising a peroxidase or a peroxidase conjugate and a specificsubstrate for the peroxidase, in the absence of peroxide.

The peroxidase may be a free peroxidase but for assay purposes ispreferably a peroxidase bound to a specific binding component of anassay, to form a peroxidase conjugate. The peroxidase conjugate ispreferably a conjugate between a peroxidase and an antigen or anantibody, most preferably an antibody. The peroxidase is preferablyhorseradish peroxidase.

The peroxidase conjugate may be prepared using, for example,sulfhydryl-maleimide coupling (Ishikawa, E., (1980), Immunoassay suppl,1, 1-16; Duncan, R. J. S., et al, Anal. Biochem., 132, 68-73),disulphide-thiol exchange (Carlsson, J., et al, (1978), Biochem, J., 173723-737), periodate oxidation (Nakane, P. K., et al, (1974), J.Histochem. Cytochem, 22, 1084-1091) or glutaraldehyde coupling(Aurameas, S. (1969), Immunochem., 6, 43-72; Aurameas, S., et al,(1971), Immunochem, 8, 1175-1179).

The peroxide may be any peroxide (for example, an organic peroxide) butis preferably hydrogen peroxide.

The stabilising effect is particularly marked in dilute solution.Preferably the concentration of peroxidase or peroxidase conjugate isbetween 10⁻⁶ and 10⁻⁹ M , and most preferably about 10⁻⁹ M (theseconcentrations being based on peroxidase).

The specific substrate is in an amount effective to stabilise thepoxidase or peroxidase conjugate. For example, where the peroxidase ishorseradish peroxidase (free or as a conjugate) and the specificsubstrate is TMB, the amount of TMB is preferably in the range 0.01 to0.1 mg/ml.

The solution is buffered at a pH compatible with the peroxidase.Preferably the solution is buffered at a pH from pH 4 to pH 8, morepreferably from pH 5 to pH 7 and most preferably at about pH 6. Asuitable buffer is 0.1M sodium acetate with citric acid at pH 6.

The solution preferably includes from 0.1 to 5% (w/v) of serum protein,most preferably about 0.2% (w/v). A suitable serum protein is bovineserum albumin. The serum protein assists stability of the peroxidase andalso, where the solution is to be used in an immunoassy application,reduces the level of non-specific binding.

A surfactant may also be included in the solution to assist further inreducing non-specific binding. Suitably from 0.01 to 0.1% (v/v) of asurfactant is added, preferably about 0.02% (v/v). For example, 0.02%(v/v) Tween (Trade Mark) may be included in the solution.

According to a second aspect of the invention we provide a method forstabilising the peroxidase activity of a buffered aqueous solutioncontaining a peroxidase or a peroxidase conjugate, comprising adding tothe solution an amount of a specific substrate for the peroxidase, inthe absence of peroxide, effective to stabilise the peroxidase activityof the solution.

In the course of research, we have discovered that the solubility of TBin an aqueous medium may be advantageously enhanced by the additon of aparticular member of the family of cyclic oligosaccharides known ascyclodextrins.

According to a third aspect of the invention, we provide a TMBperoxidase-substrate reagent consisting of an aqueous solutioncomprising TMB and β-cyclodextrin in solution.

The β-cyclodextrin acts to solubilise the otherwise sparingly solubleTMB, it is thought, by taking the molecules up into the cavity formed atthe centre of the cyclic oligosaccharide.

The TMB is preferably at a concentration suitable for use as a substratefor a peroxidase-containing reagent such as is, for example, the subjectof the first aspect of the invention. Suitably the concentration of TMBis from 0.02 to 0.3 mg/ml,more preferably from 0.02 to 0.1 mg/ml, mostpreferably about 0.1 mg/ml

The β-cyclodextrin is preferably at a concentration effective tosolubilise the TMB. Suitably the β-cyclodextrin is at a concentrationfrom 0.025 to 0.25% (w/v), most preferably about 0.25% (w/v).

Preferably the, TMB peroxidase-substrate reagent additionally comprisesa peroxide, for example, hydrogen peroxide. The concentration ofhydrogen peroxide is preferably from 0.002 to 0.02% (v/v) mostpreferably about 0.005% (v/v).

The TMB peroxidase-substrate reagent may be buffered to avoid pHfluctuations during mixing of assay reagents.

According to a fourth aspect of the invention we provide a method forpreparing a TMB preoxidase-substrate reagent of the third aspect of theinvention comprising forming an aqueous solution comprising TMB andβ-cyclodextrin. Preferably the TMB is first dissolved in an organicsolvent, for example, dimethylsulphoxide (DMSO) and then added to anaqueous soluton including β-cyclodextrin.

One or both of the reagents of the first and third aspects of theinvention may be included in an assay reagent kit. Preferably the assayreagent kit is an ELISA kit comprising a horseradish peroxidase-antibodyreagent of the first aspect of the invention and a TMBperoxidase-substrate reagent of the third aspect of the invention.

THE INVENTION IS NOW ILLUSTRATED BY THE FOLLOWING EXAMPLES ANDCOMPARATIVE EXAMPLES. COMPARATIVE EXAMPLE A

An experiment was conducted to measure the stability of an HRP solution.

A peroxidase solution comprising 0.95 μg/ml HRP in a 0.1M sodiumacetate/citric acid buffer (pH 6) with 0.2%. (v/v) bovine serum albuminand 0.02% (v/v) Tween (Trade Mark)was freshly prepared. The enzymeactivity was measured by adding 10 μl of the peroxidase solution to 1ml. of a substrate solution, again freshly prepared, which comprised 0.1mg/ml TMB and 0.0044% (v/v) hydrogen peroxide in a 0.1M sodiumacetate/citric acid buffer (pH 6) and measuring the OD₆₅₀ after 20seconds. This measurement was repeated after the peroxidase solution hadbeen stored at 37° C. The results are shown in Table 1 below.

EXAMPLE 1

The experiment described in Comparative Example A was conducted with theaddition of 0.1 mg/ml TMB to the peroxidase solution. The results areshown in Table 1 below.

                  TABLE 1    ______________________________________                     OD.sub.650                     Day 0 Day 3    ______________________________________    Example 1          1.020   0.588    Comparative Example A                       1.250   0.188    ______________________________________

These results show that the enzyme activity of HRP is 58% conserved whenstored in the presence of TMB, compared with 15% activity conservationwhen stored without TMB.

COMPARATIVE EXAMPLE B

An experiment was conducted to measure the stability of an HRP-antibodyconjugate in solution.

HRP was conjugated to a monoclonal antibody (in this Example, a mousemonoclonal antibody having specificity to oestone-3-glucuronide) usingan adaptation of the glutaraldehyde method of Avrameas (loc.cit.) 100mgat HRP was dissolved in 500 μl of 0.05 bicarbonate buffer (pH9.5) towhich was added 500μl of 11% (W/V) glutaraldehyde prepared in the samebuffer. The reaction was conducted at room temperature (20° C.-25° C.)for two hours with gentle shaking. The reaction mixture was then appliedto a PD10 column (Pharmacia Ltd) which had previously been equilibratedwith 0.5M bicarbonate buffer (pH9.5). Elution was achieved with the samebuffer and those fractions containing activated HRP were pooled.Antibody (2-3 mg/ml) in 0.05M bicarbonate buffer (pH9.5) was added tothe activated HRP to give a mass ratio of 6:1 of activated HRP toantibody. The reaction was conducted at 4° C. for 16-21 hours afterwhich the antibody-HRP conjugate was purified by gel filtation,typically on a TSIC G3000SN column (Toya Soda, Japan).

A peroxidase conjugate solution comprising an HRP-antibody conjugate at2nM HRP in a 0.1M sodium acetate/citric acid buffer (pE 6) with 0.2%(v/v) bovine serum albumin and 0.02% (v/v) Tween (Trade Mark) wasfreshly prepared. The enzyme activity-was measured by adding 20 μl ofthe peroxidase-conjugate solution of the composition described inComparative Example A and measuring the OD₆₅₀ after 2 minutes. Thismeasurement was repeated after storing at 37° C. The results are shownin Table 2 below.

EXAMPLE 2

The experiment described in Comparative Example B was conducted with theaddition of 0.1 mg/ml TMB to the peroxidase-conjugate solution. Theresults are shown in Table 2 below.

                  TABLE 2    ______________________________________                 OD.sub.650                 Day 0    Day 1   Day 16    ______________________________________    Example 2      0.463      0.427   0.413    Comparative Example B                   0.486      0.008   0.000    ______________________________________

These results show that the enzyme activity of the HRP-antibodyconjugate was 89% conserved after 16 days of storage, at an assayconcentration, in a buffer containing TMB. This compares with 100% lossof activity in an unstabilised solution, stored for the same time.

COMPARATIVE EXAMPLE C

An experiment was conducted to measure the stability of a TMB substratesolution.

A TMB substrate solution was prepared by taking a 10 mg/ml solution ofTMB in dimethyl sulphoxide (DMSO) and diluting it 1:100 into a 0.1Msodium acetate/citric acid buffer (pH 6) to which 0.0044% (v/v) H₂ O₂had been added. Samples of the substrate were stored at 4° C., 20° C.and 50° C. and the OD₆₅₀ of aliquots of each sample after mixing with anHRP-antibody conjugate solution (2 nM based on peroxidase) was measured.The results are given in Table 3 below. and are expressed as apercentage of a control (freshly prepared substrate solution).

                  TABLE 3    ______________________________________    Days                    Storage Temperature    Storage   4° C.  RT     50° C.    ______________________________________    0         94.7          94.7   94.7    3         99.1          93.3   66.2    7         77.2          55.6   74.6    21        31.4          32.7   66.3    33        24.3          33.7   55.8    ______________________________________

EXAMPLE 3

The experiment described in Comparative Example C was conducted with theaddition of 0.25% (w/v) β-cyclodextrin. The results are shown in Table 4below.

                  TABLE 4    ______________________________________    Days                    Storage Temperature    Storage   4° C.  RT     50° C.    ______________________________________     0        46.2          46.2   46.2     3        55            57.1   53.9     7        60.9          63.4   62.5    21        57.1          55.4   60.5    33        42.8          52.7   46.9    62        38.5          --     32    ______________________________________

These results show the enhanced storage properties afforded by the useof β-cyclodextrin when compared to the results given for ComparativeExample C. No crystallisation of TMB was observed in the experimentdescribed in Example 3.

It will be understood that the invention is described above by way ofexample only and modifications of detail may be made within the scope ofthe invention.

We claim:
 1. A tetramethylbenzidine peroxidase-substrate reagentcomprising an aqueous solution of tetramethylbenzidine and an amount ofβ-cyclodextrin in an amount sufficient to solubilize thetetramethylbenzidine.
 2. The tetramethylbenzidine peroxidase-substratereagent according to claim 1, further comprising a peroxide.
 3. A methodfor preparing a tetramethylbenzidine peroxidase-substrate reagentcomprising forming an aqueous solution comprising tetramethylbenzidineand an amount of β-cyclodextrin sufficient to solubilize thetetramethylbenzidine.
 4. The method according to claim 3, whereintetramethylbenzidine is dissolved in an organic solvent and subsequentlyadded to an aqueous solution containing β-cyclodextrin.
 5. A method ofincreasing the stability of tetramethylbenzidine in an aqueous solutionover time comprising adding tetramethylbenzidine to an aqueous solutioncomprising β-cyclodextrin.
 6. The method of claim 5, whereintetramethylbenzidine is dissolved in an organic solvent and subsequentlyadded to said aqueous solution containing β-cyclodextrin.